O. Kovalyova, T. Ashcheulova, K. Kysylenko

Kharkiv National Medical University

Introduction. Hypertension is the most common chronic disease that has up to 20.0-30.0 % of the adult population of the planet. The presence of concomitant diseases, including obesity worsens the course and prognosis of Hypertension. Therefore, one of the pressing and studying problems at this time in the whole World is obesity and diseases associated with it. Along with obesity, an important factor in the risk of cardiovascular events, is a lipid metabolism disorder. In recent years, the concept has been formulated, according to which in the pathogenesis of lipid metabolism disoder an important role is played by the inflammatory process, mediated by cytokines. Interleukin-22, as shown by the results of previous studies, has a direct positive relationship with many cardiometabolic risk factors, including sex, smoking, and body mass index. However, the issue of interleukin-22 implication in the pathogenesis of obesity, dyslipidemia, especially in relation to exogenous postprandial hyperlipemia, is not sufficiently studied on the clinical level in hypertensive patients whis obesity.

Aim. The study is devoted to determining the parameters of the lipid metabolism and the serum level of interleukin-22, as well as the relationship between them, in patients with hypertension, depending on the presence of excess body weight or concomitant obesity.

Materials and methods. 80 patients with hypertension were examined. All patients were divided into three groups: group 1 (n = 19; 23.8 %) – patients with hypertension whis normal body weight, group 2 (n = 30; 37.5 %) – hypertensive patients with excess body weight, group 3 (n = 31; 38.8 %) – hypertensive patients with obesity. The control group included 12 healthy individuals. Levels of serum interleukin-22 were studied by using set Bender Medsystems® Human IL-22 Platinum ELISA.

Results. According to the results of the study, in patients with hypertension of the third group there is a maximum content of total cholesterol, triglycerides, low-density lipoprotein cholesterol, very low density lipoprotein cholesterol, atherogenic index, remnant cholesterol and apolipoprotein B. The minimum content of high-density lipoprotein cholesterol is observed in the second and third groups of patients with hypertension. When comparing the parameters of lipid metabolism in the main groups of patients with hypertension and the control group, a significant increase in all atherogenic parameters in the main groups was revealed (p < 0.001). These data suggest that dyslipidemia is directly or indirectly involved in the mechanism of increasing blood pressure and the development of hypertension. Thus, hypercholesterolemia and dyslipidemia can directly affect the tone of peripheral vessels and, accordingly, on indicators of arterial pressure.

It was noted that in hypertensive patients with excessive body weight and obesity revealed basal hypercholesterolemia, hypertriglyceridemia, hypoalphacholesterolemia, increased cholesterol levels of low density lipoprotein and cholesterol of very low density lipoprotein, and also the disturbance of lipid metabolism tolerance in the postprandial period, which is manifested by an increase the content of total cholesterol, triglycerides, cholesterol of low density lipoprotein, cholesterol of lipoproteins is very low density and decrease cholesterol of high density lipoprotein.

More significant positive correlations of interleukin-22 with lipid metabolism parameters (total cholesterol, triglycerides, low-density lipoprotein cholesterol, high density lipoprotein cholesterol, remnant cholesterol and atherogenic index) in patients with hypertension with concomitant obesity were found compared with a group of hypertensive patients without no signs of excessive body weight or obesity.

Conclusions. Thus, the data obtained may indicate an interleukin-22 hypertensive effect. And the presence of close correlation relations of the investigated cytokine with parameters of the lipid spectrum may indicate that it is involved in increasing the severity of lipid metabolism disorders.

References

1. Bezrodnaya LV. Arterial Hypertension and Dislipidemia. Health of Ukraine. 2007;8:28-29.
2. Global health risk factors: mortality and disease burden due to some underlying risk factors. World Health Organization, 2015 [Electronic Resource]. Mode of access: URL: http://http://apps.who.int/iris/bitstream/10665/44203/8/9789244563878_rus.pdf. – Title from the screen.
3. Kovalenko VN, Talayeva TV, Bratus VV. Inflammation and oxidative stress in cardiovascular disease. Journal of the National Academy of Medical Sciences of Ukraine. 2012;18(4):461-474.
4. Krovyakova TV, Lebedev PA. Postprandial hyperlipemia as a factor of coronary atherosclerosis in patients with metabolic syndrome, the possibility of correction by rosuvastatin. Cardiovascular therapy and prevention. 2010;9(8):23-28.
5. Mitchenko OI, Lavryk AS, Romanov VY, Chulaevska IV, Shkreba AO. Factors of cardiovascular risk in patients with morbid obesity and ways for the medical, non-medical and surgical correction. Heart and vessels. 2013;2:98-105.
6. Samoylenko EY, Naumov VG, Tvorogova MG. Effect of atorvastatin therapy on postprandial lipemia indicators and inflammatory factors in patients with ischemic heart disease. Cardiology. 2007;2:4-8.
7. Talayeva TV, Malinovskaya IE, Tretiyak IV. Alimentary lipid overload and impaired tolerance to them as factors of atherogenesis, development and progression of ischemic heart disease. Ukrainian Cardiology Journal. 2004;1:72-79.
8. Tyrenko VV, Bogdanov AN, Sysoeva NN. Efficiency and safety of various combinations of lipid-lowering therapy in patients with metabolic syndrome. Heart. 2005;7(6):371-373.
9. Alvim R, Mourao-Junior C, Magalhaes G, Oliveira C, Krieger J, Mill J et al. Non-HDL cholesterol is a good predictor of the risk of increased arterial stiffness in postmenopausal women in an urban Brazilian population. Clinics. 2017;72(2):106-110. https://doi.org/10.6061/clinics/2017(02)07
10. Catapano A, Reiner Z, Backer G, Graham I, Taskinen M-R, Wiklund O et al. EAS/EAS Guidelines for the management of dyslipidemias. Eur Heart J. 2011;32:1769-1818.
11. Dalmas E, Donath MY. A role for interleukin-22 in the alleviation of metabolic syndrome. Nature Medicine. 2014;20:1379-1381. https://doi.org/10.1038/nm.3748
12. Dudakov JA, Hanash AM, van den Brink MRM. Interleukin-22: immunobiology and pathology. Annual Review Immunology. 2015;33:747-785. https://doi.org/10.1146/annurev-immunol-032414-112123
13. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, Jarratt MT et al. AJC editor’s consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008;1:102-105. https://doi.org/10.1016/j.amjcard.2008.10.004
14. Harari G, Green MS, Magid A, Shira Z. Non-HDL-C a better predictor of mortality than LDL-C. Am J Cardiol. 2017;119(8): 1193-1198. https://doi.org/10.1016/j.amjcard.2017.01.008
15. Herder C, Kannenberg M, Carstensen-Kirberg M, Huth C, Meisinger C, Koenig W et al. Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study. Cardiovasc. Diabetol. 2017;16:17-29. https://doi.org/10.1186/s12933-017-0498-6
16. Perk J, Backer G, Perk J. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Prevent Cardiol. 2012;19(4):585-667. https://doi.org/10.1177/2047487312450228
17. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316-322. https://doi.org/10.1016/j.jacc.2008.10.024
18. Rutz S, Wang X, Ouyang W. The IL-20 subfamily of cytokines – from host defence to tissue homeostasis. Nature Reviews Immunology. 2014;14:783-795. https://doi.org/10.1038/nri3766
19. Simone G, Devereux R, Chinali M, Roman M, Best L, Welty T. Risk Factors for Arterial Hypertension in Adult With Initial Optimal Blood Pressure. Hypertension. 2006;47:162-167. https://doi.org/10.1161/01.HYP.0000199103.40105.b5
20. Zilversmit DV. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60(3):473-485. https://doi.org/10.1161/01.CIR.60.3.473